Amylin's Once-Weekly Bydureon Clears Major Cardiac Safety Hurdle
This article was originally published in The Pink Sheet Daily
Executive Summary
Extensive data on immediate and extended release exenatide can be "leveraged and applied" to speed development of a once-monthly injectable, which is ready for Phase III.